- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 976765, 7 pages
Loss of RASSF1A Expression in Colorectal Cancer and Its Association with K-ras Status
1Department of Medical Oncology, Cancer Center, The State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, 37 Guo Xue Xiang, Chengdu, Sichuan 610041, China
2Department of Pathology, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, China
Received 6 April 2013; Accepted 29 May 2013
Academic Editor: Renfu Shao
Copyright © 2013 Dan Cao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- J. Y. Fang and B. C. Richardson, “The MAPK signalling pathways and colorectal cancer,” The Lancet Oncology, vol. 6, no. 5, pp. 322–327, 2005.
- T. Ahlquist, I. Bottillo, S. A. Danielsen et al., “RAS signaling in colorectal carcinomas through alterations of RAS, RAF, NF1, and/or RASSF1A,” Neoplasia, vol. 10, no. 7, pp. 680–686, 2008.
- E. Santos, D. Martin Zanca, and E. P. Reddy, “Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient,” Science, vol. 223, no. 4637, pp. 661–664, 1984.
- S. Salerno, V. Bazan, R. M. Tomasino et al., “Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype,” Annals of Oncology, vol. 13, no. 9, pp. 1438–1446, 2002.
- S. Ogino, K. Nosho, G. J. Kirkner et al., “CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer,” Gut, vol. 58, no. 1, pp. 90–96, 2009.
- G. P. Pfeifer and R. Dammann, “Methylation of the tumor suppressor gene RASSF1A in human tumors,” Biochemistry, vol. 70, no. 5, pp. 576–583, 2005.
- L. B. Hesson, W. N. Cooper, and F. Latif, “The role of RASSF1A methylation in cancer,” Disease Markers, vol. 23, no. 1-2, pp. 73–87, 2007.
- S. H. Park, J. J. Kim, J. S. Chung et al., “RASSF1A suppresses the activated K-Ras-induced oxidative DNA damage,” Biochemical and Biophysical Research Communications, vol. 408, no. 1, pp. 149–153, 2011.
- H. Donninger, M. D. Vos, and G. J. Clark, “The RASSF1A tumor suppressor,” Journal of Cell Science, vol. 120, no. 18, pp. 3163–3172, 2007.
- D. G. Burbee, E. Forgacs, S. Zöchbauer-Müller et al., “Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression,” Journal of the National Cancer Institute, vol. 93, no. 9, pp. 691–699, 2001.
- I. Kuzmin, J. W. Gillespie, A. Protopopov et al., “The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells,” Cancer Research, vol. 62, no. 12, pp. 3498–3502, 2002.
- T. Wang, H. Liu, Y. Chen, W. Liu, J. Yu, and G. Wu, “Methylation associated inactivation of RASSF1A and its synergistic effect with activated K-Ras in nasopharyngeal carcinoma,” Journal of Experimental and Clinical Cancer Research, vol. 28, no. 1, article 160, 2009.
- R. Bhagat, S. Chadaga, C. S. Premalata, et al., “Aberrant promoter methylation of the RASSF1A and APC genes in epithelial ovarian carcinoma development,” Cellular Oncology, vol. 35, no. 6, pp. 473–479, 2012.
- H. Chen, M. Suzuki, Y. Nakamura et al., “Aberrant methylation of RASGRF2 and RASSF1A in human non-small cell lung cancer,” Oncology Reports, vol. 15, no. 5, pp. 1281–1285, 2006.
- S. K. Kee, J. Y. Lee, M. J. Kim et al., “Hypermethylation of the Ras association domain family 1A (RASSF1A) gene in gallbladder cancer,” Molecules and Cells, vol. 24, no. 3, pp. 364–371, 2007.
- P. H. Y. Lo, D. Xie, K. C. Chan et al., “Reduced expression of RASSF1A in esophageal and nasopharyngeal carcinomas significantly correlates with tumor stage,” Cancer Letters, vol. 257, no. 2, pp. 199–205, 2007.
- M.-G. Lee, H.-Y. Kim, D.-S. Byun et al., “Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma,” Cancer Research, vol. 61, no. 18, pp. 6688–6692, 2001.
- M. D. Vos, C. A. Ellis, A. Bell, M. J. Birrer, and G. J. Clark, “Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis,” Journal of Biological Chemistry, vol. 275, no. 46, pp. 35669–35672, 2000.
- W. Yeo, W.-L. Wong, N. Wong, B. K. Law, G. M. Tse, and S. Zhong, “High frequency of promoter hypermethylation of RASSF1A in tumorous and non-tumourous tissue of breast cancer,” Pathology, vol. 37, no. 2, pp. 125–130, 2005.
- D.-H. Kim, J. S. Kim, J.-H. Park et al., “Relationship of Ras association domain family 1 methylation and K-Ras mutation in primary non-small cell lung cancer,” Cancer Research, vol. 63, no. 19, pp. 6206–6211, 2003.
- B. Gao, X.-J. Xie, C. Huang et al., “RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers,” Cancer Research, vol. 68, no. 1, pp. 22–25, 2008.
- J. M. A. Pijnenborg, G. C. Dam-de Veen, N. Kisters et al., “RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer,” Annals of Oncology, vol. 18, no. 3, pp. 491–497, 2007.
- E. Azizi, A. Kittai, and P. Kozuch, “Antiepidermal growth factor receptor monoclonal antibodies: applications in colorectal cancer,” Chemotherapy Research and Practice, vol. 2012, Article ID 198197, 15 pages, 2012.
- X. Cui, Y. Shirai, T. Wakai, N. Yokoyama, S. Hirano, and K. Hatakeyama, “Aberrant expression of pRb and p16INK4a, alone or in combination, indicates poor outcome after resection in patients with colorectal carcinoma,” Human Pathology, vol. 35, no. 10, pp. 1189–1195, 2004.
- N. S. Goldstein and M. Armin, “Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system,” Cancer, vol. 92, no. 5, pp. 1331–1346, 2001.
- X. Cui, T. Wakai, Y. Shirai, K. Hatakeyama, and S. Hirano, “Chronic oral exposure to inorganic arsenate interferes with methylation status of p16INK4a and RASSF1A and induces lung cancer in A/J mice,” Toxicological Sciences, vol. 91, no. 2, pp. 372–381, 2006.
- E. Miranda, A. Destro, A. Malesci et al., “Genetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancer,” British Journal of Cancer, vol. 95, no. 8, pp. 1101–1107, 2006.
- G. Poulogiannis, F. Luo, and M. J. Arends, “RAS signalling in the colorectum in health and disease,” Cell Communication and Adhesion, vol. 19, no. 1, pp. 1–9, 2012.
- M. Spugnardi, S. Tommasi, R. Dammann, G. P. Pfeifer, and D. S. B. Hoon, “Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma,” Cancer Research, vol. 63, no. 7, pp. 1639–1643, 2003.
- S. J. Cohen, R. B. Cohen, and N. J. Meropol, “Targeting signal transduction pathways in colorectal cancer: more than skin deep,” Journal of Clinical Oncology, vol. 23, no. 23, pp. 5374–5385, 2005.
- N. Yanagawa, G. Tamura, H. Oizumi, M. Endoh, M. Sadahiro, and T. Motoyama, “Inverse correlation between EGFR mutation and FHIT, RASSFlA and RUNX3 methylation in lung adenocarcinoma: relation with smoking status,” Anticancer Research, vol. 31, no. 4, pp. 1211–1214, 2011.